Signal
Labcorp and BD Partner to Expand HPV Screening Access Across Multiple Care Settings
- Category
- · Ecosystem Shift · Global
- Date
- October 23, 2026
- Source
- OVUM
Summary
Labcorp will become the first commercial lab to offer the FDA-approved BD Onclarity HPV Assay for both clinician and self-collected samples. Launching in late 2026, the initiative spans clinics, patient service centers, and at-home environments to improve cervical cancer screening rates.
Positions inside Oncology and Sexual & Reproductive are shifting, and the useful question is which neighbouring companies are affected. Watch for follow-on moves from the investors, incumbents, and new entrants named here.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.